Children in Scotland diagnosed with a brain tumour that has a specific genetic mutation can now be treated on the NHS with a kinder, more effective targeted therapy.
It’s used in combination with another medicine, trametinib, and both can be administered at home as they are taken orally. This means fewer hospital visits.
The news follows the approval given in April this year by the National Institute for Health and Care Excellence (NICE).
Current standard treatment for the condition typically involves surgery – where that’s possible – chemotherapy and/or radiotherapy. But less than 30% of children diagnosed with high-grade gliomas survive for five years or more and the treatment often has brutal side effects.
Outcomes for low grade gliomas – the most common childhood brain tumour – are better at a 90% survival rate following surgery. But chemotherapy may also be prescribed whereas this treatment means improved quality of life for patients as clinical trials showed its side effects were rare.
The combination medication is the first targeted treatment to be made available on the NHS for paediatric gliomas. It is already licensed for use in the USA, and for use in the UK in adults with the BRAF mutation who have some types of lung and skin cancers.
The two drugs work together to block the growth signal coming from the mutant BRAF protein, slowing or even stopping the tumour from growing.
Brain tumours affect around 500 children a year in the UK, of whom between 150 to 175 may have a glioma and fewer still will have the BRAF mutation. But despite the small numbers involved, this is the first progress made in treating the disease in years.
In 2008, research carried out by Dr David Jones which was funded by The Brain Tumour Charity (then known as the Samantha Dickson Brain Tumour Trust), identified a BRAF mutation that was common in pilocytic astrocytoma brain tumours.
This was the first time that a specific genetic change had been detected in these tumour types and it paved the way for drug development as it could then become a target for diagnostic tests, changing the research landscape for low grade brain tumours in children.
Dr Jones now leads the EVEREST Centre in Germany, which carries out research into paediatric low grade brain tumours.
Dr Michele Afif, Chief Executive at The Brain Tumour Charity, said: “We are delighted that the Scottish Medicines Consortium has joined NICE in approving the first new treatment for paediatric brain tumours in decades.
“We hope that this will be the first of many new treatments that will ensure our community can live longer and better lives.”
To find out more about The Brain Tumour Charity, visit:
New research led by a team of scientists from Queen’s University Belfast and the Cancer Research UK (CRUK) Scotland Institute in Glasgow have made a series of groundbreaking discoveries into tumour biology that may be used to deliver a more effective personalised medicine approach for patients with bowel (colorectal) cancer.
Bowel cancer is the fourth most common cancer in the UK, with around 42,900 new bowel cancer cases and around 16,600 bowel cancer deaths in the UK every year, a statistic that highlights the need for new ways to treat patients with this aggressive disease.
The new study, funded by Cancer Research UK and published today in the prestigious journal Nature Genetics, used a unique and innovative approach developed in Belfast, to identify a set of previously unseen molecular patterns in tumour tissue that provides new information related to treatment response and risk of disease progression.
These remarkable results mean that clinicians and scientists can now draw more information from a patient’s tumour tissue which may lead to better treatment options.
Previously, the most common approach for identifying groups of tumours based on their biological signalling, known as molecular subtyping, used information about how active individual genes are within tumour tissue.
The subtypes identified using this method have shaped understanding of cancer development, progression and response to therapy over the last decade and served as the basis for numerous clinical trials and pre-clinical studies.
Dr Philip Dunne, Reader in Molecular Pathology from the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast and senior author of the study, explains: “While looking at patterns across individual genes has revealed remarkable insights into cancer signalling, advances in laboratory research over the last decade have shown that assessing activity in groups of closely related genes in combination can provide new understanding that isn’t apparent when using the traditional single gene approaches.”
Given the potential value of this new pathway approach, researchers from Queen’s University Belfast, the CRUK Scotland Institute, University of Zurich, University of Oxford alongside a multinational collaborative group proposed a new data-driven method for reclassification of bowel cancer, which has been published in this new groundbreaking study.
By assembling genes into biological pathways prior to the development of molecular subtypes, the team rearranged tumours into a series of new groups, based on activity across a complex network of cancer-related signalling; all of which appears to be critical in predicting how well a tumour will respond to different treatments such as chemotherapy and radiotherapy.
To ensure that scientists and clinicians around the world can immediately access these data and test this new subtyping approach, the team have released a freely available classification tool that allows the Belfast-developed approach to be used on tumour samples in any research lab.
Dr Sudhir Malla, Postdoctoral Research Fellow from the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast and first author of the study commented: “By developing an unrestricted classification tool for the cancer research community, it means that researchers from around the world can reproduce our finding on data emerging from their own collections of tumour samples, to identify biological pathways that cancer cells switch on or off to control their movement, growth and response to their environment.”
Professor Owen Sansom, Director of the Cancer Research UK Scotland Institute in Glasgow, who co-authored the study said: “The research presented today in Nature Genetics exemplifies the value of collaborative research between scientists and clinicians.
“Studies such as this are essential to enable us to understand the complexities of a patient’s tumour and will be used in our pre-clinical laboratories to identify novel treatments specifically targeting the biological patterns we have identified.”
Dr Sam Godfrey, Research Information Lead at Cancer Research UK, said: “Cancer is perhaps the most complex disease we face, and no single treatment will ever beat it.
“Cancer Research UK is delighted to have funded this innovative research, an important step towards giving doctors the insight to see which therapy can best exploit an individual cancer’s weakness.
“Research like this could lead to better and more precise treatments for the thousands of people diagnosed with bowel cancer every year in Scotland.”
The team are now applying their new subtyping approach on tumour samples derived from clinical trials run in the UK, to build the essential clinical evidence needed before the new method can be used to make clinical decision about which treatments a patient should be offered.
The Windsor Framework, agreed by the Prime Minister and European Commission President, replaces the old Northern Ireland Protocol, providing a new legal and UK constitutional framework.
Fundamentally rewriting the Treaty with new ‘Stormont Brake’ means UK can veto new EU goods laws if they are not supported by both communities in Northern Ireland
New green lane removes any sense of a border in Irish Sea
Northern Ireland to benefit from same VAT, food and drink and medicines as the rest of the UK
A new way forward for a prosperous, stable future for Northern Ireland has been set out, rewriting the Treaty to fix the practical problems for the people and businesses of Northern Ireland, protects Northern Ireland’s place within our Union, and restores the balance of the Belfast (Good Friday) Agreement in all its dimensions.
The Windsor Framework, agreed by the Prime Minister and European Commission President yesterday, replaces the old Northern Ireland Protocol, dealing with the issues it has created and providing a new legal and UK constitutional framework.
It delivers free-flowing trade in goods between Great Britain and Northern Ireland by removing any sense of the border in the Irish Sea for goods staying within the UK. These goods will travel as normal through a new green lane without red tape or unnecessary checks, with the only checks remaining designed to prevent smuggling or crime.
It protects Northern Ireland’s place in our Union, replacing swathes of EU laws with UK laws and ensuring the people of Northern Ireland can benefit from the same tax policies, food and drink, medicines, and parcels as the rest of the UK.
It puts the people of Northern Ireland in charge with active democratic consent. The Agreement rewrites the Treaty text with a new Stormont Brake that means the UK can veto new EU goods laws if they are not supported by both communities in Northern Ireland, which goes far beyond previous agreements or discussions on the old Protocol.
At Monday’s press conference, Prime Minister Rishi Sunak said: “Today’s agreement is written in the language of laws and treaties. But really, it’s about much more than that.
“It’s about stability in Northern Ireland. It’s about real people and real businesses. It’s about showing that our Union, that has lasted for centuries, can and will endure.
“And it’s about breaking down the barriers between us. Setting aside the arguments that have for too long, divided us. And remembering the fellow feeling that defines us: This family of nations – this United Kingdom.”
The Windsor Framework delivers free-flowing movement of goods between Northern Ireland and Great Britain and removes any sense of a border in the Irish Sea within the UK:
A new green lane (the UK internal market scheme) means traders moving goods destined for Northern Ireland will be freed of unnecessary paperwork, checks and duties, using only ordinary commercial information rather than burdensome customs bureaucracy or complex certification requirements for agrifood. The same type of standard commercial information used when moving goods from Birmingham to the Isle of Wight will be used Birmingham to Belfast. All goods destined for the EU will use the red lane.
All requirements have been scrapped for trade from Northern Ireland to Great Britain on a permanent basis, including the requirement for export declarations.
The green lane will be expanded to include food retailers such as supermarkets and hospitality businesses, significantly reducing SPS checks and costly paperwork, and ensuring choice for consumers on supermarket shelves. A single supermarket truck who previously had to provide 500 certificates can now instead make a straightforward commitment that goods will stay in Northern Ireland. Retailers will mark goods as “not for EU”, with a phased rollout of this requirement to give them time to adjust.
Chilled meats like sausages, which were banned under the old Protocol, can move freely into Northern Ireland like other retail food products.
Parcels from people or businesses in Great Britain can now be sent to friends, family, and consumers in Northern Ireland as they are today, without customs declarations, processes or extra costs under the old Protocol. Parcels sent business to business will travel via the green lane.
The Windsor Framework protects Northern Ireland’s place in the Union:
The same medicines, in the same packs, with the same labels, will be available across the UK, without the need for barcode scanning requirements under the old Protocol. The UK will license all medicines for all UK citizens, including novel medicines like cancer drugs, rather than the European Medicines Agency under the old Protocol. NI’s healthcare industry will have full access to both UK and EU markets, supporting jobs and investment through a dual regulatory regime.
Pets can also now travel freely with their owners across the UK, without expensive health treatments like rabies or documentation from a vet. Pet owners in Northern Ireland won’t have to do a thing when travelling to GB. Where they’re not moving on to Ireland or the rest of the EU, GB owners with microchipped pets can either easily sign up for a lifetime travel document for their pet, available online and electronically in a matter of minutes, or an equally seamless process built into the booking processfor a flight or ferry.
Previously banned iconic plants like English oak trees and seed potatoes will once again move easily within the UK without the bureaucratic checks and costly certification under the old Protocol and instead use a similar process to the Plant Passport scheme that already exists in Great Britain. This will end restrictions that hampered consumer choice and damaged business whilst protecting the long-standing single epidemiological area on the island of Ireland.
The legal text of the Treaty has been amended, so that critical VAT and excisechanges will apply to the whole of the UK. This means that zero-rates of VAT on energy saving materials like solar panels and alcohol duty reforms will now apply in Northern Ireland.
The UK Government can continue to provide generous and targeted subsidiesacross the UK. The ‘reach-back’ risks under the old Protocol have been addressed with new stringent tests, so there are now almost no circumstances in which the Protocol applies to UK subsidies, providing certainty for businesses to trade and invest in Northern Ireland. We expect more than 98% of Northern Ireland subsidies to be unaffected in practice.
The Windsor Framework safeguards sovereignty and fixes the democratic deficit by putting the people of Northern Ireland in charge:
The new Stormont Brake means the democratically elected Northern Ireland Assembly can oppose new EU goods rules that would have significant and lasting effects on everyday lives in Northern Ireland. They will do so on the same basis as the ‘petition of concern’ mechanism in the Belfast (Good Friday) Agreement, needing the support of 30 members from at least two parties. The Stormont Brake has been introduced by fundamentally rewriting the Treaty and goes significantly further than the ‘all or nothing vote’ under the old Protocol every four years at most.
Over 1,700 of EU law have been removed, and with it ECJ interpretation and oversight in areas like VAT, medicines, and food safety – so the UK Government can decide and UK courts can interpret. The minimal set of EU rules – less than 3% – apply to preserve the privileged, unrestricted access for Northern Ireland businesses to the whole of the EU Single Market and avoid a hard border on the island of Ireland.
The agreement concludes months of intensive discussions between the UK and EU to address real world issues and needs of the people of Northern Ireland.
Providing reassurance for the future, the UK and EU have agreed to work together to anticipate and deal with any other issues that may emerge and have made a joint declaration to resolve issues through dialogue, rather than formal dispute proceedings.
Alongside ‘The Windsor Framework: a new way forward’, the Government has published the full range of legal texts that underpin the Windsor Framework. These solutions put arrangements in Northern Ireland on an entirely new footing, with far-reaching changes to the old Protocol to provide lasting certainty and stability for citizens and businesses in Northern Ireland.
To give businesses and individuals time to prepare, the implementation of the agreement will be phased in, with some of the new arrangements for goods, agrifood, pets and plant movements introduced later this year and the remainder in 2024. In the meantime, the current temporary standstill arrangements will continue to apply.
The UK Government will no longer proceed with the Northern Ireland Protocol Bill, as the UK and EU have come to a negotiated agreement. Similarly, the agreement will mean the EU withdrawing all of the legal actions it has launched against the UK.
Prime Minister Rishi Sunak makes a speech on the Windsor Framework:
Good afternoon.
All our thoughts are with Detective Chief Inspector John Caldwell and his family after last week’s abhorrent shooting in Omagh.
A man of extraordinary courage, his first thought was to protect the children he had been coaching.
President Von der Leyen and I stand united with the people and leaders of all communities across Northern Ireland.
Those trying to drag us back to the past will never succeed.
This afternoon, I welcomed President Von der Leyen to Windsor to continue our discussions about the Northern Ireland Protocol.
I’m pleased to report that we have now made a decisive breakthrough.
Together, we have changed the original Protocol and are today announcing the new Windsor Framework.
Today’s agreement:
Delivers smooth flowing trade within the whole United Kingdom.
Protects Northern Ireland’s place in our Union.
And safeguards sovereignty for the people of Northern Ireland.
These negotiations have not always been easy, but I’d like to pay an enormous personal tribute to Ursula for her vision in recognising the possibility of a new way forward.
And to my colleagues the Foreign and Northern Ireland Secretaries for their steadfast leadership.
The United Kingdom and the European Union may have had our differences in the past, but we are allies, trading partners, and friends … something that we’ve seen clearly in the past year as we joined with others, to support Ukraine.
This is the beginning of a new chapter in our relationship.
For a quarter of a century the Belfast (Good Friday) Agreement has endured because at its heart is respect for the aspirations and identities of all communities.
Today’s agreement is about preserving that delicate balance and charting a new way forward for the people of Northern Ireland.
I am standing here today because I believe that we have found ways to end the uncertainty and challenge for the people of Northern Ireland.
We have taken three big steps forward.
First, today’s agreement delivers the smooth flow of trade within the United Kingdom.
Goods destined for Northern Ireland will travel through a new Green Lane, with a separate Red Lane for goods at risk of moving onto the EU.
In the Green Lane, burdensome customs bureaucracy will be scrapped.
It means food retailers like supermarkets, restaurants and wholesalers will no longer need hundreds of certificates for every lorry.
And we will end the situation where food made to UK rules could not be sent to and sold in Northern Ireland.
This means that if food is available on the supermarket shelves in Great Britain … then it will be available on supermarket shelves in Northern Ireland.
And unlike the Protocol, today’s agreement means people sending parcels to friends and family or doing their shopping online, will have to complete no customs paperwork.
This means we have removed any sense of a border in the Irish Sea.
Second, we have protected Northern Ireland’s place in the Union.
We’ve amended the legal text of the Protocol to ensure we can make critical VAT and excise changes for the whole of the UK…
…for example on alcohol duty, meaning our reforms to cut the cost of a pint in the pub will now apply in Northern Ireland.
The same quintessentially British products like trees, plants, and seed potatoes – will again be available in Northern Ireland’s garden centres.
Onerous requirements on pet travel have been removed.
And today’s agreement also delivers a landmark settlement on medicines.
From now on, drugs approved for use by the UK’s medicines regulator… will be automatically available in every pharmacy and hospital in Northern Ireland.
Third, today’s agreement safeguards sovereignty for the people of Northern Ireland.
The only EU law that applies in Northern Ireland under the Framework … is the minimum necessary to avoid a hard border with Ireland and allow Northern Irish businesses to continue accessing the EU market.
But I know that many people in Northern Ireland are also worried about being subject to changes to EU goods laws.
To address that, today’s agreement introduces a new Stormont Brake.
Many had called for Stormont to have a say over these laws.
But the Stormont Brake goes further and means that Stormont can in fact stop them from applying in Northern Ireland.
This will establish a clear process through which the democratically elected Assembly can pull an emergency brake … for changes to EU goods rules that would have significant, and lasting effects on everyday lives. If the brake is pulled, the UK government will have a veto.
This gives the institutions of the Good Friday Agreement in Northern Ireland a powerful new safeguard, based on cross community consent.
I believe the Windsor Framework marks a turning point for the people of Northern Ireland.
It fixes the practical problems they face.
It preserves the balance of the Belfast Good Friday Agreement.
Of course, parties will want to consider the agreement in detail, a process that will need time and care.
Today’s agreement is written in the language of laws and treaties.
But really, it’s about much more than that.
It’s about stability in Northern Ireland.
It’s about real people and real businesses.
It’s about showing that our Union, that has lasted for centuries, can and will endure.
And it’s about breaking down the barriers between us.
Setting aside the arguments that for too long, have divided us.
And remembering the fellow feeling that defines us: This family of nations – this United Kingdom.
Researchers at Queen’s University Belfast have uncovered a key process that contributes to vision loss and blindness in people with diabetes. The findings could lead to new treatments that can be used before any irreversible vision loss has occurred.
Diabetic retinopathy is a common complication of diabetes and occurs when high blood sugar levels damage the cells at the back of the eye, known as the retina. There are no current treatments that prevent the advancement of diabetic retinopathy from its early to late stages, beyond the careful management of diabetes itself. As a result, a significant proportion of people with diabetes still progress to the vision-threatening complications of the disease.
As the number of people with diabetes continues to increase globally, there is an urgent need for new treatment strategies, particularly those that target the early stages of the disease to prevent vision loss.
The retina demands a high oxygen and nutrient supply to function properly. This is met by an elaborate network of blood vessels that maintain a constant flow of blood even during daily fluctuations in blood and eye pressure. The ability of the blood vessels to maintain blood flow at a steady level is called blood flow autoregulation. The disruption of this process is one of the earliest effects of diabetes in the retina.
The breakthrough made by researchers at Queen’s University Belfast pinpoints the cause of these early changes to the retina.
The study, published in the US journal JCI Insight, has discovered that the loss of blood flow autoregulation during diabetes is caused by the disruption of a protein called TRPV2. Furthermore, they show that disruption of blood flow autoregulation even in the absence of diabetes causes damage closely resembling that seen in diabetic retinopathy.
The research team are hopeful that these findings will be used to inform the development of new treatments that preserve vision in people with diabetes.
Professor Tim Curtis, Deputy Director at the Wellcome-Wolfson Institute for Experimental Medicine at Queen’s and corresponding author, explains: “We are excited about the new insights that this study provides, which explain how the retina is damaged during the early stages of diabetes.
“By identifying TRPV2 as a key protein involved in diabetes-related vision loss, we have a new target and opportunity to develop treatments that halt the advancement of diabetic retinopathy.”
The study was funded by the Biotechnology and Biological Sciences Research Council and the Department for the Economy Postgraduate Studentship scheme.
A new vaccine that protects against Covid-19 is nearly 95% effective, early data from US company Moderna shows.
The latest news follows last week’s breakthrough announcement from Pfizer, and, while testing is still to be done, it’s looking more and more likely that vaccines to help bring an end to the pandemic will be available over coming months.
This study, known as the COVE study, enrolled more than 30,000 participants in the U.S. and is being conducted in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.
The primary endpoint of the Phase 3 COVE study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine. This first interim analysis was based on 95 cases, of which 90 cases of COVID-19 were observed in the placebo group versus 5 cases observed in the mRNA-1273 group, resulting in a point estimate of vaccine efficacy of 94.5% (p <0.0001).
Moderna says it is a “great day” and they plan to apply for approval to use the vaccine in the next few weeks.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible”, said Stéphane Bancel, Chief Executive Officer of Moderna.
“All along, we have known that each day matters. This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease.
“This milestone is only possible because of the hard work and sacrifices of so many. I want to thank the thousands of participants in our Phase 1, Phase 2 and Phase 3 studies, and the staff at our clinical trial sites who have been on the front lines of the fight against the virus.
“They are an inspiration to us all. I want to thank the NIH, particularly NIAID, for their scientific leadership including through years of foundational research on potential pandemic threats at the Vaccine Research Center that led to the discovery of the best way to make Spike protein antigens that are being used in our vaccine and others.
“I want to thank our partners at BARDA and Operation Warp Speed who have been instrumental to accelerating our progress to this point. Finally, I want to thank the Moderna team, our suppliers and our partners, for their tireless work across research, development and manufacturing of the vaccine.
“We look forward to the next milestones of submitting for an EUA in the U.S., and regulatory filings in countries around the world, while we continue to collect data on the safety and efficacy of the vaccine in the COVE study. We remain committed to and focused on doing our part to help end the COVID-19 pandemic.”
Ground-breaking coronavirus treatment approved for use across the NHS from today
Government-funded UK trial showed drug saved lives by significantly reducing risk of death in hospitalised patients who require oxygen
Government ensures drug is available across all NHS healthcare settings and across the whole of the UK with immediate effect
Thousands of lives could be saved in the UK as the government immediately authorises the NHS to use the world’s first coronavirus treatment proven to reduce the risk of death.
Dexamethasone, an anti-inflammatory steriod drug, has been immediately approved to treat all UK hospitalised COVID-19 patients requiring oxygen, including those on ventilators, from today.
The drug has been proven to reduce the risk of death significantly in COVID-19 patients on ventilation by as much as 35% and patients on oxygen by 20%, reducing the total 28-day mortality rate by 17%.
Funded by the UK government, via the National Institute for Health Research (NIHR) and UK Research and Innovation (UKRI), the Oxford University UK RECOVERY trial is the first clinical trial anywhere in the world to show a treatment provides significant impact in reducing patient mortality.
The government has taken action to secure supplies of dexamethasone in the UK, buying additional stocks ahead of time in the event of a positive trial outcome. This means there is already enough treatment for over 200,000 people from stockpiles alone.
Health Secretary Matt Hancock said: “I’m absolutely delighted that today we can announce the world’s first successful clinical trial for a treatment for COVID-19. This astounding breakthrough is testament to the incredible work being done by our scientists behind the scenes.
“From today the standard treatment for COVID-19 will include dexamethasone, helping save thousands of lives while we deal with this terrible virus.
“Guided by the science, the UK is leading the way in the global fight against coronavirus – with the best clinical trials, the best vaccine development and the best immunology research in the world.
“I want to thank the brilliant scientists at Oxford University, the thousands of patients who took part in the study, and my own team, led by Professor Jonathan Van-Tam, who has done such a brilliant job driving this work.”
The drug has also been added to the government’s parallel export list, which bans companies from buying medicines meant for UK patients and selling them on for a higher price in another country. This will protect supply for UK patients by enforcing regulatory action on those who flout the restrictions.
Throughout the pandemic, the government has supported British research with millions of pounds of funding for clinical trials into the most promising and innovative medicines in our fight against this new virus, including £2.1 million for the RECOVERY trial.
This clinical trial is testament to the success we see when government, scientists and the NHS – including 175 NHS trusts across the whole of the UK – work together. With over 177,000 patients enrolled, it’s the largest randomised clinical trial anywhere in the world and will continue to trial other medicines, such as azithromycin and lopinavir-ritonavir.
Deputy Chief Medical Officer, Professor Jonathan Van-Tam, said: “The RECOVERY trial is an outstanding example of the UK leading the world with an impressive study capable of delivering robust answers to critical questions. Although these data have not yet been peer-reviewed.
“The positive findings on dexamethasone follow the disappointing findings on hydroxychloroquine. Together these 2 results illustrate the power of properly conducted clinical trials and the inherent danger of assuming things work without robust data.
“Whilst tempting to do otherwise, it is always better to wait for the evidence. On the dexamethasone findings, this is very encouraging because the signal on reduced mortality applies to many of the patients admitted to hospitals and the drug is comparatively low priced and available worldwide.”
The UK is a world leader in global science and medicine industries. This British trial will now affect the global response to this pandemic.
This breakthrough has only been made possible through the rigour of world-class and world-leading British life-sciences. The government backed British science from the very beginning of this pandemic and today has proven that this was the right call.
The vital information collected by UK researchers will also be used by other countries to reduce mortality rates worldwide.
Prime Minister Boris Johnson welcomed the news at yesterday’s daily press briefing. He said: “I am delighted that the biggest breakthrough yet has been made by a fantastic team of scientists right here in the UK.
“I am not really qualified to announce on this drug and its effects but I will ask Sir Patrick and Professor Horby to say more in a moment.
“But I am so proud of these British scientists, backed by UK Government funding, who have led the first robust clinical trial anywhere in the world to find a coronavirus treatment proven to reduce the risk of death.
“And I am very grateful to the thousands of patients in this country who volunteered for the trials – thank you.
“This drug – dexamethasone – can now be made available across the NHS. And we have taken steps to ensure we have enough supplies, even in the event of a second peak.
“Of course, while the chances of dying from Covid-19 have been significantly reduced by this treatment, they are still far too high. So we must redouble our research efforts and we certainly will.
“But today, there is genuine cause to celebrate a great, British achievement and the benefits it will bring not just in this country but around the world.”
Sainsburys Blackhall are proud to have supported Dorothy and Joanna Bissett with their fundraising for Breakthrough Breast Cancer.
The ladies had organised a sponsored 5K run through Inverleith Park on 13 September to raise funds for Breakthrough breast cancer and Sainsburys Bakery Manager Scott McDowell from our Blackhall store made and donated 150 pink cupcakes to raise funds too!
